Apart from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and in shape sufficient to tolerate FCR therapy, should still be great candidates with the latter, with the gain remaining this treatment method is usually completed in 6 months even though ibrutinib should be taken indefinitely. This option would be notably important for non-com